Understanding neuromuscular disorders in chronic fatigue syndrome.
Exercise
Fatigue Syndrome, Chronic
/ physiopathology
Heat-Shock Proteins
/ metabolism
Humans
Lipid Peroxides
/ metabolism
Muscle, Skeletal
/ physiopathology
Muscular Diseases
/ physiopathology
Oxidative Stress
Potassium
/ metabolism
Reactive Oxygen Species
/ metabolism
Transcranial Magnetic Stimulation
central fatigue
chronic fatigue syndrome
heat shock proteins
myalgic encephalomyelitis
neuromuscular disorders
neurophysiology
oxidative stress
peripheral fatigue
physiology
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
19
11
2019
entrez:
10
12
2019
pubmed:
10
12
2019
medline:
4
6
2020
Statut:
epublish
Résumé
Muscle failure has been demonstrated in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Neurophysiological tools demonstrate the existence of both central and peripheral fatigue in these patients. Central fatigue is deduced from the reduced amplitude of myopotentials evoked by transcranial magnetic stimulation of the motor cortex as well as by the muscle response to interpolated twitches during sustained fatiguing efforts. An impaired muscle membrane conduction velocity assessed by the reduced amplitude and lengthened duration of myopotentials evoked by direct muscle stimulation is the defining feature of peripheral fatigue. Some patients with ME/CFS show an increased oxidative stress response to exercise. The formation of lipid hydroperoxides in the sarcolemma, which alters ionic fluxes, could explain the reduction of muscle membrane excitability and potassium outflow often measured in these patients. In patients with ME/CFS, the formation of heat shock proteins (HSPs) is also reduced. Because HSPs protect muscle cells against the deleterious effects of reactive oxygen species, the lack of their production could explain the augmented oxidative stress and the consecutive alterations of myopotentials which could open a way for future treatment of ME/CFS.
Identifiants
pubmed: 31814961
doi: 10.12688/f1000research.18660.1
pmc: PMC6883394
pii:
doi:
Substances chimiques
Heat-Shock Proteins
0
Lipid Peroxides
0
Reactive Oxygen Species
0
Potassium
RWP5GA015D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright: © 2019 Jammes Y and Retornaz F.
Déclaration de conflit d'intérêts
No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.
Références
Life Sci. 2001 Mar 16;68(17):2037-49
pubmed: 11388705
Innate Immun. 2016 Apr;22(3):162-7
pubmed: 26921255
Front Pediatr. 2018 Sep 04;6:242
pubmed: 30234078
Clin Neurophysiol. 1999 Nov;110(11):1883-91
pubmed: 10576483
J Clin Pathol. 2007 Feb;60(2):117-9
pubmed: 16935963
Redox Rep. 2000;5(1):35-41
pubmed: 10905542
J Exp Biol. 2013 Oct 1;216(Pt 19):3620-6
pubmed: 23788701
J Physiol. 2006 Oct 1;576(Pt 1):1
pubmed: 16901938
Acta Physiol Scand Suppl. 1990;593:1-63
pubmed: 2239345
Free Radic Biol Med. 2005 Sep 1;39(5):584-9
pubmed: 16085177
Neurosci Lett. 2003 Jan 2;335(3):151-4
pubmed: 12531455
BMJ. 1988 Oct 22;297(6655):1014-7
pubmed: 3142592
J Peripher Nerv Syst. 1998;3(4):267-76
pubmed: 10970127
J Comp Neurol. 2003 Jun 23;461(2):140-50
pubmed: 12724833
Neuromuscul Disord. 2003 Aug;13(6):479-84
pubmed: 12899875
PLoS One. 2013 Nov 28;8(11):e81155
pubmed: 24312270
J Transl Med. 2018 Apr 12;16(1):97
pubmed: 29650052
Immunol Today. 1993 Mar;14(3):115-8
pubmed: 8466626
J Transl Med. 2016 Aug 31;14:251
pubmed: 27580693
Ann Intern Med. 1994 Dec 15;121(12):953-9
pubmed: 7978722
Eur J Appl Physiol Occup Physiol. 1995;71(2-3):207-14
pubmed: 7588690
Pflugers Arch. 2009 Nov;459(1):143-50
pubmed: 19701650
PLoS One. 2015 Apr 02;10(4):e0122982
pubmed: 25836975
Free Radic Biol Med. 2000 Dec 15;29(12):1252-9
pubmed: 11118815
Br J Sports Med. 1999 Oct;33(5):352-6
pubmed: 10522640
Front Biosci. 2008 Jan 01;13:1328-39
pubmed: 17981633
Am J Physiol. 1996 Sep;271(3 Pt 1):L383-91
pubmed: 8843786
Int J Clin Pract. 2003 May;57(4):262-4
pubmed: 12800454
Clin Neurophysiol. 2004 Nov;115(11):2518-24
pubmed: 15465441
Brain. 1991 Feb;114 ( Pt 1A):85-98
pubmed: 1998892
Lancet. 2006 Jan 28;367(9507):346-55
pubmed: 16443043
J Appl Physiol (1985). 1988 Jun;64(6):2306-13
pubmed: 3136123
Clin Neurophysiol. 2017 Jan;128(1):44-55
pubmed: 27866119
J Intern Med. 2005 Mar;257(3):299-310
pubmed: 15715687
Neurology. 1996 Dec;47(6):1410-4
pubmed: 8960719
Med Sci Sports Exerc. 2001 Sep;33(9):1463-70
pubmed: 11528333
J Transl Med. 2018 Oct 1;16(1):268
pubmed: 30285773
Free Radic Biol Med. 1999 Feb;26(3-4):454-62
pubmed: 9895238
J Appl Physiol (1985). 1992 May;72(5):1631-48
pubmed: 1601767
Neurology. 1993 Jan;43(1):125-31
pubmed: 8423875
J Intern Med. 2012 Jul;272(1):74-84
pubmed: 22112145
Respir Physiol Neurobiol. 2004 Nov 30;144(1):81-90
pubmed: 15522705
Clin Neurophysiol. 2004 Oct;115(10):2372-81
pubmed: 15351380
Eur J Neurol. 1999 Jan;6(1):63-9
pubmed: 10209352
PLoS One. 2019 Mar 21;14(3):e0212193
pubmed: 30897114
Curr Rheumatol Rep. 2017 Jan;19(1):1
pubmed: 28116577
Med Sci Sports Exerc. 2007 Jun;39(6):964-8
pubmed: 17545886